Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
16.93
-2.85 (-14.41%)
At close: Nov 12, 2024, 4:00 PM
17.77
+0.84 (4.96%)
After-hours: Nov 12, 2024, 4:10 PM EST
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RNAC stock have an average target of 40.8, with a low estimate of 39 and a high estimate of 43. The average target predicts an increase of 140.99% from the current stock price of 16.93.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RNAC stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 5 | 5 | 5 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $41 | Strong Buy | Maintains | $45 → $41 | +142.17% | Nov 8, 2024 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +142.17% | Nov 8, 2024 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +142.17% | Oct 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +165.80% | Sep 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +165.80% | Sep 4, 2024 |
Financial Forecast
Revenue This Year
44.01M
from 26.00M
Increased by 69.22%
Revenue Next Year
7.48M
from 44.01M
Decreased by -83.00%
EPS This Year
-4.82
from -49.80
EPS Next Year
-3.61
from -4.82
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 53.8M | 25.2M | 25.2M | ||
| Avg | 44.0M | 7.5M | 11.2M | ||
| Low | 38.5M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 107.1% | -42.7% | 236.9% | ||
| Avg | 69.2% | -83.0% | 50.0% | ||
| Low | 48.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.25 | -1.71 | -1.69 |
| Avg | -4.82 | -3.61 | -4.48 |
| Low | -4.93 | -4.71 | -6.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.